Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Cytosolic β-glucosidase (GBA3) is a neutral β-glucocerebrosidase.1,2 It is composed of a single glycoside hydrolase domain and hydrolyzes glucosyl- and galactosylceramides. GBA3 is expressed in the liver, small intestine, colon, spleen, and kidneys.3 In vitro, knockdown of GBA3 inhibits mitotic arrest and promotes resistance to paclitaxel (Item No. 10461) in colon cancer cells.4 Tumor levels of GBA3 are lower in patients with hepatocellular carcinoma and decreased expression is associated with poor prognosis.5 Unlike GBA1, polymorphisms in GBA3 are not associated with Gaucher disease, a lysosomal storage disorder.6 Cayman’s GBA3 (human, recombinant) protein can be used for enzyme activity assays. This protein consists of 480 amino acids and has a calculated molecular weight of 55 kDa.
WARNING This product is not for human or veterinary use.
1. Klotho-
2. Glucosylceramidases and malignancies in mammals. Biochimie 125, 267-280 (2016).
3. Molecular cloning and expression of a novel klotho-
4. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6), 498-512 (2007).
5. Decreased expression of GBA3 correlates with a poor prognosis in hepatocellular carcinoma patients. Neoplasma 67(5), 1139-1145 (2020).
6. Mutations in the gene encoding cytosolic β-